Drug
Bnt323
Bnt323: highest development phase Phase 1/2, developed by BioNTech. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- BioNTech
Trials
| Drug | Phase | Indication |
|---|---|---|
| BNT323 NCT06827236 | Phase 1/2 | Locally Advanced Breast Cancer |
Latest
No recent events.
Follow Bnt323 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.